After Frontline Immunotherapy Fails: Panel Maps Next Moves in Melanoma
Panel maps post-progression care in metastatic melanoma: reserve BRAF/MEK therapy for urgent need, escalate immunotherapy, and steer fit patients toward cellular therapy and trials.